Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Avogaro

Showing results (61-70 of 426) with videos related to

Pageof 43
Sort By:
Stroke|May 26, 2005
Endothelial progenitor cells in cerebrovascular diseaseGian Paolo Fadini, Carlo Agostini, Angelo Avogaro
Vascular Pharmacology|February 2, 2013
Restoring stem cell mobilization to promote vascular repair in diabetesMattia Albiero, Angelo Avogaro, Gian Paolo Fadini
Current Pharmaceutical Design|July 13, 2013
Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protectionAngelo Avogaro, Saula de Kreutzenberg, Gianpaolo Fadini
Current Diabetes Reviews|January 29, 2008
Endothelial progenitor cells and vascular biology in diabetes mellitus: current knowledge and future perspectivesGian P Fadini, Carlo Agostini, Angelo Avogaro
Current Pharmaceutical Design|February 19, 2014
Circulating cellular players in vascular calcificationMattia Albiero, Angelo Avogaro, Gian Paolo Fadini
Diabetes, Obesity & Metabolism|July 4, 2023
Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trialsMauro Rigato, Gian Paolo Fadini, Angelo Avogaro
Diabetes Research and Clinical Practice|May 3, 2026
DPP-4 inhibitors in current diabetes care: their foundational role in treating to targetAngelo Avogaro, Enrico Fiaccadori, Maria Rosaria Rizzo
American Journal of Respiratory Cell and Molecular Biology|August 19, 2006
Pathophysiology of circulating progenitor cells in pulmonary disease and parallels with cardiovascular diseaseGian Paolo Fadini, Angelo Avogaro, Carlo Agostini
BMJ Open Diabetes Research & Care|February 17, 2018
Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting SystemGian Paolo Fadini, Mayur Sarangdhar, Angelo Avogaro
Experimental Hematology|September 25, 2007
Critical assessment of putative endothelial progenitor phenotypesGian Paolo Fadini, Angelo Avogaro, Carlo Agostini
Pageof 43

Showing results (61-70 of 426) with videos related to

Sort By:
Pageof 43
Stroke|May 26, 2005
Endothelial progenitor cells in cerebrovascular diseaseGian Paolo Fadini, Carlo Agostini, Angelo Avogaro
Vascular Pharmacology|February 2, 2013
Restoring stem cell mobilization to promote vascular repair in diabetesMattia Albiero, Angelo Avogaro, Gian Paolo Fadini
Current Pharmaceutical Design|July 13, 2013
Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protectionAngelo Avogaro, Saula de Kreutzenberg, Gianpaolo Fadini
Current Diabetes Reviews|January 29, 2008
Endothelial progenitor cells and vascular biology in diabetes mellitus: current knowledge and future perspectivesGian P Fadini, Carlo Agostini, Angelo Avogaro
Current Pharmaceutical Design|February 19, 2014
Circulating cellular players in vascular calcificationMattia Albiero, Angelo Avogaro, Gian Paolo Fadini
Diabetes, Obesity & Metabolism|July 4, 2023
Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trialsMauro Rigato, Gian Paolo Fadini, Angelo Avogaro
Diabetes Research and Clinical Practice|May 3, 2026
DPP-4 inhibitors in current diabetes care: their foundational role in treating to targetAngelo Avogaro, Enrico Fiaccadori, Maria Rosaria Rizzo
American Journal of Respiratory Cell and Molecular Biology|August 19, 2006
Pathophysiology of circulating progenitor cells in pulmonary disease and parallels with cardiovascular diseaseGian Paolo Fadini, Angelo Avogaro, Carlo Agostini
BMJ Open Diabetes Research & Care|February 17, 2018
Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting SystemGian Paolo Fadini, Mayur Sarangdhar, Angelo Avogaro
Experimental Hematology|September 25, 2007
Critical assessment of putative endothelial progenitor phenotypesGian Paolo Fadini, Angelo Avogaro, Carlo Agostini
Pageof 43